专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06936638B2 Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto 失效
标题翻译：腺嘌呤核苷酸转位酶（ANT）的配体及其相关的组合物和方法
公开(公告)号：US06936638B2
公开(公告)日：2005-08-30
申请号：US10741595
申请日：2003-12-19
申请人： Soumitra S. Ghosh , Yazhong Pei , Xiao-Qing Tang , Spiros J. Liras , Michael K. Ahlijanian
发明人： Soumitra S. Ghosh , Yazhong Pei , Xiao-Qing Tang , Spiros J. Liras , Michael K. Ahlijanian
IPC分类号： A61K31/185 , A61P25/00 , C07C65/24 , C07C65/30 , C07C65/40 , C07C69/94 , C07D263/56 , C07D263/57 , C07D277/66 , C07D307/80 , C07D333/16 , C07D333/24 , C07D333/56 , C07D333/60 , A61K31/19 , C07D313/04
CPC分类号： C07D263/57 , A61K31/185 , C07C65/24 , C07C65/30 , C07C65/40 , C07C69/94 , C07D277/66 , C07D307/80 , C07D333/16 , C07D333/24 , C07D333/56 , C07D333/60
摘要： Compounds which have utility in the treatment of conditions associated with altered mitochondrial function. The compounds have the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.
摘要翻译：可用于治疗与改变的线粒体功能相关的病症的化合物。所述化合物具有以下结构（I）：包括其立体异构体，前药和药学上可接受的盐，其中R 1，R 2，R 3， >，R 4，R 5和R 6如本文所定义。还公开了含有结构（I）化合物的药物组合物以及与其用途有关的方法。

2. 发明授权

US06552076B2 Compounds for altering mitochondrial function and cellular responses 失效
标题翻译：用于改变线粒体功能和细胞反应的化合物
公开(公告)号：US06552076B2
公开(公告)日：2003-04-22
申请号：US10020090
申请日：2001-12-14
申请人： Yazhong Pei , Walter H. Moos , Soumitra S. Ghosh
发明人： Yazhong Pei , Walter H. Moos , Soumitra S. Ghosh
IPC分类号： A61K3124
CPC分类号： C07C235/20 , C07C237/22 , C07C237/42 , C07D307/68
摘要： Compounds for treating diseases by altering mitochondrial function that affects cellular processes, as well as to compositions and methods related thereto. The compounds have the structure wherein R1, R2, R3 and A are as defined herein.
摘要翻译：通过改变影响细胞过程的线粒体功能来治疗疾病的化合物，以及与其相关的组合物和方法。化合物具有其中R 1，R 2，R 3和A如本文所定义的结构。

3. 发明授权

US07001729B2 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor 失效
公开(公告)号：US07001729B2
公开(公告)日：2006-02-21
申请号：US09811131
申请日：2001-03-14
申请人： Christen M. Anderson , Robert E. Davis , William Clevenger , Sandra Eileen Wiley , Scott W. Miller , Tomas R. Szabo , Soumitra S. Ghosh , Walter H. Moos , Yazhong Pei
发明人： Christen M. Anderson , Robert E. Davis , William Clevenger , Sandra Eileen Wiley , Scott W. Miller , Tomas R. Szabo , Soumitra S. Ghosh , Walter H. Moos , Yazhong Pei
IPC分类号： G01N29/00 , G01N33/573 , C12N11/00
CPC分类号： C07K14/47 , C07K2319/00 , C07K2319/07 , C07K2319/21 , C07K2319/23 , C12N15/62 , C12N2799/021
摘要： Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.

4. 发明授权

US06906175B2 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor. 失效
标题翻译：腺嘌呤核苷酸转运蛋白（ANT）的生产，新型ANT配体及其筛选试验。
公开(公告)号：US06906175B2
公开(公告)日：2005-06-14
申请号：US09809889
申请日：2001-03-16
申请人： Christen M. Anderson , Robert E. Davis , William Clevenger , Sandra Eileen Wiley , Scott W. Miller , Tomas R. Szabo , Soumitra S. Ghosh , Walter H. Moos , Yazhong Pei
发明人： Christen M. Anderson , Robert E. Davis , William Clevenger , Sandra Eileen Wiley , Scott W. Miller , Tomas R. Szabo , Soumitra S. Ghosh , Walter H. Moos , Yazhong Pei
IPC分类号： G01N33/50 , A61K31/704 , A61K31/7048 , A61K31/7056 , A61K31/7064 , A61K45/00 , A61P3/00 , A61P3/10 , A61P17/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/28 , A61P27/16 , A61P35/00 , A61P43/00 , C07H15/256 , C07H15/26 , C07K1/22 , C07K14/47 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/62 , C12P21/02 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/566 , C07K1/00 , C07K14/00
CPC分类号： C07K14/47 , C07K2319/00 , C07K2319/07 , C07K2319/21 , C07K2319/23 , C12N15/62 , C12N2799/021
摘要： Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.
摘要翻译：提供了用于产生腺嘌呤核苷酸转运蛋白（ANT）多肽和融合蛋白的组合物和方法，包括产生和使用具有调节启动子的重组表达构建体。还公开了ANT配体以及用于鉴定ANT配体的组合物和方法，结合ANT的试剂和与ANT相互作用的试剂。

5. 发明授权

US06902908B2 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor 失效
标题翻译：腺嘌呤核苷酸转运蛋白（ANT）的生产，新型ANT配体及其筛选试验
公开(公告)号：US06902908B2
公开(公告)日：2005-06-07
申请号：US09811094
申请日：2001-03-14
申请人： Christen M. Anderson , Robert E. Davis , William Clevenger , Sandra Eileen Wiley , Scott W. Miller , Tomas R. Szabo , Soumitra S. Ghosh , Walter H. Moos , Yazhong Pei
发明人： Christen M. Anderson , Robert E. Davis , William Clevenger , Sandra Eileen Wiley , Scott W. Miller , Tomas R. Szabo , Soumitra S. Ghosh , Walter H. Moos , Yazhong Pei
IPC分类号： G01N33/50 , A61K31/704 , A61K31/7048 , A61K31/7056 , A61K31/7064 , A61K45/00 , A61P3/00 , A61P3/10 , A61P17/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/28 , A61P27/16 , A61P35/00 , A61P43/00 , C07H15/256 , C07H15/26 , C07K1/22 , C07K14/47 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/62 , C12P21/02 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/566 , C12N15/00 , C07H21/04 , C12N15/63
CPC分类号： C07K14/47 , C07K2319/00 , C07K2319/07 , C07K2319/21 , C07K2319/23 , C12N15/62 , C12N2799/021
摘要： Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.
摘要翻译：提供了用于产生腺嘌呤核苷酸转运蛋白（ANT）多肽和融合蛋白的组合物和方法，包括产生和使用具有调节启动子的重组表达构建体。还公开了ANT配体以及用于鉴定ANT配体的组合物和方法，结合ANT的试剂和与ANT相互作用的试剂。

6. 发明授权

US06887670B2 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor 失效
公开(公告)号：US06887670B2
公开(公告)日：2005-05-03
申请号：US09811132
申请日：2001-03-14
申请人： Christen M. Anderson , Robert E. Davis , Tomas R. Szabo , Soumitra S. Ghosh , Walter H. Moos , Yazhong Pei
发明人： Christen M. Anderson , Robert E. Davis , Tomas R. Szabo , Soumitra S. Ghosh , Walter H. Moos , Yazhong Pei
IPC分类号： G01N33/50 , A61K31/704 , A61K31/7048 , A61K31/7056 , A61K31/7064 , A61K45/00 , A61P3/00 , A61P3/10 , A61P17/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/28 , A61P27/16 , A61P35/00 , A61P43/00 , C07H15/256 , C07H15/26 , C07K1/22 , C07K14/47 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/62 , C12P21/02 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/566 , C07K1/00 , C07K1/14 , C07K1/16 , C07K17/00
CPC分类号： C07K14/47 , C07K2319/00 , C07K2319/07 , C07K2319/21 , C07K2319/23 , C12N15/62 , C12N2799/021
摘要： Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.

7. 发明授权

US06958352B2 Compounds for inhibiting insulin secretion and methods related thereto 失效
标题翻译：用于抑制胰岛素分泌的化合物及其相关方法
公开(公告)号：US06958352B2
公开(公告)日：2005-10-25
申请号：US10364292
申请日：2003-02-10
申请人： Yazhong Pei , Soumitra S. Ghosh , Ian William James
发明人： Yazhong Pei , Soumitra S. Ghosh , Ian William James
IPC分类号： C07D295/18 , A61K31/135 , A61K31/136 , A61K31/16 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/18 , A61K31/192 , A61K31/216 , A61K31/22 , A61K31/223 , A61K31/36 , A61K31/381 , A61K31/40 , A61K31/415 , A61K31/417 , A61K31/4184 , A61K31/4245 , A61K31/426 , A61K31/428 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4439 , A61K31/445 , A61K31/495 , A61K31/5375 , A61K45/00 , A61P3/10 , A61P7/12 , A61P43/00 , C07C45/46 , C07C45/67 , C07C205/56 , C07C211/29 , C07C229/14 , C07C229/34 , C07C233/11 , C07C237/04 , C07C237/10 , C07C237/14 , C07C317/44 , C07C323/29 , C07C323/40 , C07C323/41 , C07C323/42 , C07C323/44 , C07C323/49 , C07C323/52 , C07C323/60 , C07C335/18 , C07D207/32 , C07D207/335 , C07D211/20 , C07D211/24 , C07D211/96 , C07D213/38 , C07D213/70 , C07D213/73 , C07D213/80 , C07D213/81 , C07D213/82 , C07D231/14 , C07D233/20 , C07D233/54 , C07D233/61 , C07D235/06 , C07D271/06 , C07D277/28 , C07D277/64 , C07D295/185 , C07D317/68 , C07D333/20 , C07D413/12 , C07D211/06
CPC分类号： C07D207/335 , C07C45/46 , C07C45/673 , C07C205/56 , C07C211/29 , C07C229/34 , C07C233/11 , C07C237/10 , C07C237/14 , C07C317/44 , C07C323/29 , C07C323/40 , C07C323/41 , C07C323/42 , C07C323/44 , C07C323/49 , C07C323/52 , C07C323/60 , C07C335/18 , C07C2601/02 , C07C2601/14 , C07D211/24 , C07D211/96 , C07D213/38 , C07D213/70 , C07D213/73 , C07D213/81 , C07D213/82 , C07D231/14 , C07D233/20 , C07D233/64 , C07D271/06 , C07D277/28 , C07D277/64 , C07D295/185 , C07D413/12 , C07C49/83
摘要： Compounds, compositions and methods for altering insulin secretion, particularly in the context of treatment of subjects having, or suspected of being at risk for having, diabetes mellitus. The compounds have the following structure (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein W1, W2, X, R1, R2, R3, R4, m and n are defined herein.
摘要翻译：用于改变胰岛素分泌的化合物，组合物和方法，特别是在治疗具有或怀疑患有糖尿病风险的受试者的情况下。该化合物具有以下结构（I）：包括其立体异构体，前药和药学上可接受的盐，其中W 1，W 2，X，R 1， R 2，R 2，R 3，R 4，m和n在本文中定义。

8. 发明授权

US09249181B2 C-terminal amidation of polypeptides 有权
标题翻译：多肽的C-末端酰胺化
公开(公告)号：US09249181B2
公开(公告)日：2016-02-02
申请号：US13822821
申请日：2011-09-08
申请人： Chengzao Sun , Behrouz Bruce Forood , Gary Luo , Soumitra S. Ghosh
发明人： Chengzao Sun , Behrouz Bruce Forood , Gary Luo , Soumitra S. Ghosh
IPC分类号： C07K1/00 , C07K1/107 , C07D311/88 , C07C211/27
CPC分类号： C07K1/003 , C07C211/27 , C07D311/88 , C07K1/107
摘要： There are provided compounds and methods for amidating the C-terminus of a polypeptide. The methods include reacting a polypeptide which includes a C-terminal thioester or C-terminal selenoester with any one of a defined set of auxiliary molecules under conditions suitable to produce a polypeptide adduct which includes the auxiliary molecule chemically bound at the C-terminal of the polypeptide. The auxiliary molecule can be a substituted or unsubstituted 2-phenyl-2-amino ethanethiol, a substituted or unsubstituted 2-phenyl-2-amino ethaneselenol, or a substituted xanthene. In the subsequent step, a portion of the auxiliary molecule is removed from the C-terminal of the polypeptide adduct and leaving the amide nitrogen under conditions suitable to form a C-terminal free amide polypeptide.
摘要翻译：提供了用于酰胺化多肽的C末端的化合物和方法。所述方法包括在适于产生多肽加合物的条件下使包含C-末端硫酯或C-末端硒酯的多肽与定义的一组辅助分子中的任何一种反应，所述多肽加合物包括在C末端化学键合的辅助分子多肽。辅助分子可以是取代或未取代的2-苯基-2-氨基乙硫醇，取代或未取代的2-苯基-2-氨基乙基硒酚或取代的呫吨。在随后的步骤中，一部分辅助分子从多肽加合物的C末端除去，并在适于形成C末端游离酰胺多肽的条件下离开酰胺氮。

9. 发明授权

US08603969B2 Pancreatic polypeptide family motifs and polypeptides comprising the same 失效
标题翻译：胰多肽家族基序和包含其的多肽
公开(公告)号：US08603969B2
公开(公告)日：2013-12-10
申请号：US11055098
申请日：2005-02-11
申请人： Odile Esther Levy , Carolyn M. Jodka , Soumitra S. Ghosh , David G. Parkes , Richard A. Pittner , Lawrence J. D'Souza , John S. Ahn , Kathryn S. Prickett
发明人： Odile Esther Levy , Carolyn M. Jodka , Soumitra S. Ghosh , David G. Parkes , Richard A. Pittner , Lawrence J. D'Souza , John S. Ahn , Kathryn S. Prickett
IPC分类号： A61K38/22
CPC分类号： C07K14/575 , A61K38/00 , C07K14/475
摘要： The present invention relates to novel Pancreatic Polypeptide Family (“PPF”) polypeptides. The PPF polypeptides of the invention generally include at least two PPF motif, have at least 50% sequence identity to PYY (3-36) over its length and will generally retain, at least in part, a biological activity of a PP, PYY or NPY. Preferred PPF polypeptides of the invention are those having a potency in one of the assays described herein (preferably food intake, gastric emptying, pancreatic secretion, or weight reduction assays) which is greater than the potency of PP, NPY, PYY, or PYY(3-36) in that same assay. In one aspect, the PPF polypeptides of the invention include novel PYY analog polypeptides. In another aspect, the PPF polypeptides of the invention include PPF chimeric polypeptides including a fragment of a PP family polypeptide linked to a second PP family polypeptide, wherein each of the first and second fragments includes a PPF motif. Methods of using the PPF polypeptides of the invention, and pharmaceutical compositions including the PPF polypeptides of the invention are also disclosed.
摘要翻译：本发明涉及新型胰腺多肽家族（“PPF”）多肽。本发明的PPF多肽通常包括至少两个PPF基序，其长度与PYY（3-36）具有至少50％的序列同一性，并且通常至少部分地保留PP，PYY的生物学活性或 NPY。本发明优选的PPF多肽是在本文所述测定之一（优选食物摄取，胃排空，胰腺分泌或重量减轻试验）中具有效力的那些，其大于PP，NPY，PYY或PYY的效力（ 3-36）。一方面，本发明的PPF多肽包括新的PYY类似物多肽。在另一方面，本发明的PPF多肽包括PPF嵌合多肽，其包括与第二PP家族多肽连接的PP家族多肽的片段，其中第一和第二片段中的每一个包括PPF基序。还公开了使用本发明的PPF多肽的方法和包括本发明的PPF多肽的药物组合物。

10. 发明授权

US08404637B2 GIP analog and hybrid polypeptides with selectable properties 失效
公开(公告)号：US08404637B2
公开(公告)日：2013-03-26
申请号：US11816095
申请日：2006-02-10
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
IPC分类号： A61K38/00 , A61P3/10
CPC分类号： C07K14/575 , C07K14/605 , C07K2319/00
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式